Cat. No. | Product name | CAS No. |
DCC5528 |
Wnk-in-3
Novel Allosteric WNK Kinase Inhibitor |
853298-47-2 |
DCC5529 |
Wnt/hh-in-1
Novel potent dual inhibitor of Wnt and hedgehog signalings, blocking porcupine and smoothened |
|
DCC5530 |
Wny0824
Novel dual BRD4 and PLK1 inhibitor (IC 50 values of 109 and 22 nM, respectively), showing strong antiproliferative activity against cancer cells |
|
DCC5531 |
Wo-459
Novel GPR52 agonist, dose-dependently inducing elevation of intracellular cAMP in HEK293/GPR52 cells |
1313195-84-4 |
DCC5532 |
Wp1193
Novel inhibitor of the JAK2/STAT3 pathway |
951693-87-1 |
DCC5533 |
Wp-871 Monohydrate
Main active metabolite of tazanolast, inhibiting dose-dependently compound 48/80-induced histamine release from rat peritoneal mast cells |
1184521-48-9 |
DCC5534 |
Wqe-134
Novel Dual Inhibitor of Nitric Oxide and Prostaglandin E2 Production |
|
DCC5535 |
Wr99210
Potent inhibitor of Plasmodium falciparum dihydrofolate reductase (DHFR) |
47326-86-3 |
DCC5536 |
Wrr-286
Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.6 nM |
|
DCC5537 |
Wrr-391
Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.2 nM |
|
DCC5538 |
wrr-483
Analog of K11777; Irriversible effective cysteine protease inhibitor with trypanocidal activity in cell culture and animal model with comparable efficacy to K11777. |
1076089-14-9 |
DCC5539 |
Ws-47-js03
Novel potent RET kinase inhibitor with >500-fold selectivity against KDR (Kinase insert Domain Receptor) in cellular assays |
|
DCC5540 |
Ws-691
Novel highly potent and orally active ABCB1 modulator capable of overcoming MDR, stabilizing ABCB1 by directly binding to ABCB1, stimulating the activity of ABCB1 ATPase without inhibitory activity against CYP3A4, increasing the sensitivity of SW620/Ad300 |
|
DCC5541 |
Wsj-557
Novel xanthine oxidase inhibitor |
|
DCC5542 |
Wu-07047
Simplified analog of the selective Gαq/11 inhibitor YM-25489 |
1702378-78-6 |
DCC5543 |
Wwl123
Novel α/ß-hydrolase domain 6 (ABHD6) inhibitor |
1338574-83-6 |
DCC5544 |
Wx-671
Novel urokinase inhibitor |
590368-25-2 |
DCC5545 |
Wye-687 Dihydrochloride
Potent, ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) |
1062161-90-3 |
DCC5546 |
Wyk431
Potent inhibitor of proliferation activity against a broad spectrum of human cancer cell lines, induces G2/M phase arrest and apoptosis through the PI3K/Akt pathway |
|
DCC5547 |
Xanthoangelol
Natural antibacterial agent against Gram-positive bacterial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecium and Enterococcus faecalis |
62949-76-2 |
DCC5548 |
Xantholipin
Antibiotic, exhibiting strong antibacterial activities and showing potent cytotoxicity, inhibiting HSP47 gene expression produced by Streptomyces sp |
|
DCC5549 |
Xantholipin B
Novel antibiotic, showing 3- to 10-fold greater cytotoxicity than Xantholipin against a select panel of human cancer cell lines, demonstrating powerful antimicrobial activity against both Gram-positive bacteria and fungi |